Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Therapy
Clinical trial results presented for trifunctional antibodies
June 16th, 2005
Fresenius Biotech successfully completed two phase I studies evaluating trifunctional antibodies in the treatment of breast cancer and peritoneal carcinomatosis. The results of these studies were presented by investigators from the participating universities at the American Society of Clinical Oncology (ASCO) annual meeting in Orlando, Florida. Encouraging results were achieved with the trifunctional antibody rexomun (WHO INN: ertumaxomab), which was evaluated in a clinical trial for the first time. In this multicenter phase I study including patients with metastatic breast cancer, rexomun (ertumaxomab) proved to be safe and tolerable. Seventeen...
Source: Women's Health Weekly (2005-06-16)
|
